Wall Street Analysts Think Theravance Bio (TBPH) Could Surge 27%: Read This Before Placing a BetZacks Investment Research • 02/18/22
Theravance Biopharma to Report Fourth Quarter and Full Year 2021 Financial Results on February 23, 2022PRNewsWire • 02/09/22
Theravance Biopharma, Inc. Announces Enrollment of First Patient in YUPELRI® Phase 4 StudyPRNewsWire • 01/10/22
Theravance Biopharma to Present at the 40th Annual J.P. Morgan Healthcare ConferencePRNewsWire • 01/05/22
Theravance Bio (TBPH) Down 3.7% Since Last Earnings Report: Can It Rebound?Zacks Investment Research • 12/03/21
Theravance Biopharma, Inc. (TBPH) CEO Rick Winningham on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 11/04/21
Theravance Biopharma, Inc. Reports Third Quarter 2021 Financial Results and Provides Business UpdatePRNewsWire • 11/03/21
Will Theravance Biopharma (TBPH) Report Negative Earnings Next Week? What You Should KnowZacks Investment Research • 10/27/21
Theravance Biopharma to Report Third Quarter 2021 Financial Results November 3, 2021PRNewsWire • 10/20/21
Down 51.5% in 4 Weeks, Here's Why Theravance Bio (TBPH) Looks Ripe for a TurnaroundZacks Investment Research • 09/21/21
Theravance Biopharma shares slide 34% premarket on news to cut 75% of workforce in strategic overhaulMarket Watch • 09/15/21
Theravance Biopharma, Inc. Announces Strategic Actions to Focus on Respiratory Disease PortfolioPRNewsWire • 09/15/21
Theravance Biopharma, Inc. Announces Top-line Results from a Phase 3 Study of Ampreloxetine in Patients with Symptomatic Neurogenic Orthostatic HypotensionPRNewsWire • 09/15/21
Why Is Theravance Bio (TBPH) Down 36.5% Since Last Earnings Report?Zacks Investment Research • 09/02/21